[{"orgOrder":0,"company":"Merck & Co","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Portage Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Domain Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"5-Methyltetrazole","moa":"A2AR\/BR","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.26000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Neostigmine","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"M6495","moa":"ADAMTS5","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Merck & Co","amount2":0.53000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.53000000000000003,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IDE-161","moa":"AKR1C3","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Nephrology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Thermo Fisher Scientific","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Carbon Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":1.2,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":1.2,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ US Government","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ US Government"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"United Nations Children\u2019s Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ United Nations Children\u2019s Fund","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ United Nations Children\u2019s Fund"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0.12,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hetero Drugs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Hetero","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Hetero"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Immutep"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Immutep"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Nykode Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VB10.16","moa":"APC receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Nykode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Organon","sponsor":"Dermavant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":1.2,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.2,"dosageForm":"Cream","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Dermavant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":1.2,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Qurient","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Q702","moa":"AXL\/Mer\/CSF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"ABL Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"ABL103","moa":"||B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Organon \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organon","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organon","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organon","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"QATAR","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Hematology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BRAZIL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Hematology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Imipenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Imipenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Philogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Bifikafusp Alfa","moa":"BCMA receptor\/Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mk-3655","moa":"Beta-klotho (KLB)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Eli Lilly"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Teon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TT-816","moa":"CB2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||CB2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"E7386","moa":"CBP\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"TME Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Emapticap pegol","moa":"||CCL2","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"C-C chemokine receptor type 4 (CCR4)||CCR4","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Invox Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"FS120","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"F-star Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"FS120","moa":"||CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Nectin Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NTX-1088","moa":"CD155","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Nectin Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"NTX-1088","moa":"||CD155","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Affimed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Acimtamig","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IMM60","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Portage Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"IMM60","moa":"CD1d","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Merck & Co","amount2":1.8500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8500000000000001,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Merck & Co","amount2":1.8500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8500000000000001,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"MK-5890","moa":"||CD27","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"CD276","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Ifinatamab deruxtecan","moa":"CD276","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"CD276","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"CD276","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"CD276","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"CD276","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"CD276","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"CD276","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"CD276","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"GI Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GI-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Gocatamig","moa":"CD3\/BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AMX-818","moa":"CD3\/HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA052","moa":"CD30","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA052","moa":"CD30","graph1":"Immunology","graph2":"IND Enabling","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AMG330","moa":"CD33\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Antengene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATG-037","moa":"CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Antengene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"ATG-037","moa":"||CD37","graph1":"Oncology","graph2":"Phase I","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SEA-CD40","moa":"CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Akamis Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"NG-350A","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jacobio Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"JAB-BX102","moa":"CD73","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jacobio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"JAB-BX102","moa":"||CD73","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Asher Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PDS Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PDS Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PDS Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PDS Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PDS Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PDS Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"CD8 T-cell||Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Asher Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alfa","moa":"CD8\/IL-2R","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Alpine Immune Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Davoceticept","moa":"CD80||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Alpine Immune Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Davoceticept","moa":"||CD80","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Alpine Immune Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Alpine Immune Sciences"},{"orgOrder":0,"company":"Merck & Co","sponsor":"NGM Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM831","moa":"CD85k-Fibronectin interaction (LILRB4-FN1 PPI)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"BioCity Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"BC3195","moa":"||CDH3\/P-cadherin","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Raludotatug Deruxtecan","moa":"CDH6","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Raludotatug Deruxtecan","moa":"CDH6","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Raludotatug Deruxtecan","moa":"CDH6","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Raludotatug Deruxtecan","moa":"CDH6","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Raludotatug Deruxtecan","moa":"CDH6","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Raludotatug Deruxtecan","moa":"CDH6","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Raludotatug Deruxtecan","moa":"CDH6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Qurient","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Q901","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"14-C Opevesostat","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Orion Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Orion Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AUM Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinodasertib","moa":"CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Daptomycin","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Wellmarker Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"WM-A1-3389","moa":"Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Wellmarker Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||Checkpoint protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Virbac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Milbemycin Oxime","moa":"||Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Virbac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Milbemycin Oxime","moa":"||Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-5684","moa":"Cholesterol desmolase (CYP11A1)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MK-5684","moa":"Cholesterol desmolase (CYP11A1)","graph1":"Nephrology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MK-5684","moa":"Cholesterol desmolase (CYP11A1)","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Antengene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"ATG-022","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Zhejiang Doer Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"DR30303","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Preclinical","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Phanes Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MK-2060","moa":"Coagulation factor XI (F11)","graph1":"Nephrology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MK-2060","moa":"Coagulation factor XI (F11)","graph1":"Hematology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MK-2060","moa":"Coagulation factor XI (F11)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MK-2060","moa":"Coagulation factor XI (F11)","graph1":"Nephrology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MK-2060","moa":"Coagulation factor XI (F11)","graph1":"Nephrology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MK-2060","moa":"Coagulation factor XI (F11)","graph1":"Nephrology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"MK-2060","moa":"Coagulation factor XI (F11)","graph1":"Nephrology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"NGM Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Expanded Collaboration","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Merck & Co","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.20999999999999999,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"NGM Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"InflaRx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Lyvgen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"LVGN6051","moa":"||Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Lyvgen","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Lyvgen"},{"orgOrder":0,"company":"Merck & Co","sponsor":"OncoC4","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Gotistobart","moa":"||CTLA4","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gotistobart","moa":"||CTLA4","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gotistobart","moa":"CTLA4","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ADG126","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Oncorus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"ONCR-177","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Oncorus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"ONCR-177","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Oncorus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Collaboration","leadProduct":"ONCR-177","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Oncorus","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Oncorus"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cytovation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CyPep-1","moa":"CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cytovation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CyPep-1","moa":"CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cytovation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CyPep-1","moa":"CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":1.9199999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.9199999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Opevesostat","moa":"CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Orion Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Opevesostat","moa":"CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Orion Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Opevesostat","moa":"CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Orion Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Opevesostat","moa":"CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Orion Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Opevesostat","moa":"CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Orion Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Opevesostat","moa":"CYP11A1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Opevesostat","moa":"CYP11A1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Arpraziquantel","moa":"CYP11B1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Posaconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Posaconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ankyra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"ANK-101","moa":"||Cytokine","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ADG116","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"HiberCell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"HiberCell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Harpoon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Atezolizumab","moa":"||Delta-like protein 3 (DLL3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0.65000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Harpoon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Atezolizumab","moa":"||Delta-like protein 3 (DLL3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0.68000000000000005,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":1.0700000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.0700000000000001,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ASP1570","moa":"Diacylglycerol kinase zeta (DGKZ)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Codexis","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Chord Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Cladribine","moa":"DNA","graph1":"Immunology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novocure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Temozolomide","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Teclison","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tirapazamine","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novocure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"NovoTTF-200T","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Letermovir","moa":"||DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jason A Roberts | Royal Brisbane and Women's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Nephrology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Jason A Roberts | Royal Brisbane and Women's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Jason A Roberts | Royal Brisbane and Women's Hospital"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Undisclosed","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I | Tumor-associated calcium signal transducer 2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I | Tumor-associated calcium signal transducer 2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Surface Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Merck & Co \/ Surface Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Surface Oncology"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DF9001","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"DF9001","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Nephrology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Exelixis"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ionova Life Science","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INV-1120","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ionova Life Science","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"INV-1120","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Adlai Nortye","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palupiprant","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bicara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BCA101","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Rakuten Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Cetuximab Sarotalocan","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Disitamab Vedotin","moa":"ERBB2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Acquisition","leadProduct":"Estradiol","moa":"||Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Theramex"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Evopoint Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Evopoint Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"XNW5004","moa":"EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Alendronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ACE-083","moa":"Fc fusion protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pyxis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Rexahn Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Termination","leadProduct":"RX-5902","moa":"fluoroquinolone derivatives","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Rexahn Pharmaceuticals Inc","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Rexahn Pharmaceuticals Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SPAIN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Corifollitropin Alfa","moa":"Follicle stimulating hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Corifollitropin Alfa","moa":"Follicle stimulating hormone receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.A.E","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Follitropin Beta","moa":"Follicle stimulating hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Clesrovimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Clesrovimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Clesrovimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Clesrovimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Clesrovimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Clesrovimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"HiberCell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"HiberCell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Efinopegdutide","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Merck & Co","amount2":0.87,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.87,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Efinopegdutide","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efinopegdutide","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efinopegdutide","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Efinopegdutide","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efinopegdutide","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efinopegdutide","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efinopegdutide","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Perrigo Company plc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Lava Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LAVA-1207","moa":"Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Lava Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"LAVA-1207","moa":"||Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"CG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"CG0070","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"CG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"CG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"CG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Linnaeus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LNS8801","moa":"GPER","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Linnaeus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LNS8801","moa":"||GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Linnaeus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"LNS8801","moa":"||GPER","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Linnaeus Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Linnaeus Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tepotinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tepotinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tepotinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CT-0508","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"HER-Vaxx","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Avelumab","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Triumvira Immunologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"TAC01-HER2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"||HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efprezimod Alfa","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0.42999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.42999999999999999,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hm Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Hm Capital","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Hm Capital"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0.35999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.35999999999999999,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ US Government","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ US Government"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"||High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ulonivirine","moa":"HIV-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"Organon \/ IQVIA"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NETHERLANDS","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NETHERLANDS","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Richmond Pharmacology","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Organon \/ Richmond Pharmacology","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Richmond Pharmacology"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"University of North Carolina","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"UT Southwestern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Gilead Sciences"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Gilead Sciences"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Undisclosed","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Undisclosed","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"IO Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"IO Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"IO Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ IO Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ IO Biotech"},{"orgOrder":0,"company":"Merck & Co","sponsor":"CytomX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CX-801","moa":"IFN-alpha-2b","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"CytomX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"CX-801","moa":"||IFN-alpha-2b","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"PDS0101","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ PDS Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ PDS Biotechnology"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Repertoire Immune Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"RPTR-147","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sotio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sotio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nanrilkefusp Alfa","moa":"IL15RA","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Simcha Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST-067","moa":"IL-18 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Simcha Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||IL-18 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Philogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cue Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Cue Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Cue Biopharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MK-1484","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"MK-1484","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":1.6599999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.6599999999999999,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Neurogene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NL-201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Werewolf Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"WTX-124","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Werewolf Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Surface Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Casdozokitug","moa":"||IL27","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Surface Oncology","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ Surface Oncology"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Alkermes Plc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Nemvaleukin Alpha","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Alkermes Plc","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Alkermes Plc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Medicenna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MDNA11","moa":"IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Medicenna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Medicenna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"THOR-707","moa":"IL-2R beta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"THOR-707","moa":"IL-2R beta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"THOR-707","moa":"IL-2R beta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"THOR-707","moa":"||IL-2R beta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Sanofi"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Mural Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nemvaleukin Alfa","moa":"IL2RA","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Genome & Company","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"GEN-001","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Genome & Company","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Probiotic","year":"2022","type":"Collaboration","leadProduct":"GEN-001","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jenner Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Jenner Institute","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Jenner Institute"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Personalis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"V940","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"VelosBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Zilovertamab","moa":"Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":2.75,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":2.75,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Feladilimab","moa":"Inducible T-cell costimulator","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Feladilimab","moa":"||Inducible T-cell costimulator","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Acceleron Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":11.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":11.5,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Acceleron Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":11.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":11.5,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.45000000000000001,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Lithium Carbonate","moa":"Inositol-1(or 4)-monophosphatase 1 | Glycogen synthase kinase-3","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Organon","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Bempegaldesleukin","moa":"||interleukins: interleukin-2 analogues and derivatives; PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Nektar Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Nektar Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NT-I7","moa":"interleukins: interleukin-7 analogues and derivatives; Fc fusion protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Olomorasib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"InventisBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Garsorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jacobio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Intismeran","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Intismeran","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Intismeran","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Moderna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Intismeran","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Moderna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-1084","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-1084","moa":"KRAS G12C","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-1084","moa":"KRAS G12C","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MK-1084","moa":"KRAS G12C","graph1":"Nephrology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MK-1084","moa":"KRAS G12C","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-1084","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-1084","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MK-1084","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MK-1084","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"MK-4830","moa":"||Leukocyte immunoglobulin-like receptor B2 (LILRB2)","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"NGM Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"NGM707","moa":"Leukocyte immunoglobulin-like receptor B2 (LILRB2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"ALX Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"ALX Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"ALX Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Magrolimab","moa":"Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Arch Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"AO-176","moa":"||Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Arch Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Arch Oncology"},{"orgOrder":0,"company":"Merck & Co","sponsor":"NextCure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NC410","moa":"||Leukocyte-associated Ig-like receptor 1 (LAIR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"NextCure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NC410","moa":"Leukocyte-associated Ig-like receptor 1 (LAIR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"NGM Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM438","moa":"Leukocyte-associated Ig-like receptor 1 (LAIR1)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"ImmunOs Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"IOS-1002","moa":"LILRB1\/LILRB2\/KIR3DL1","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"HRS-5346","moa":"Lipoprotein A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":1.97,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.97,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MK-3543","moa":"LSD1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alfa","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alfa","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Favezelimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Favezelimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Favezelimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Favezelimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Favezelimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Favezelimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Favezelimab","moa":"||Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Imago BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Merck & Co","amount2":1.3500000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":1.3500000000000001,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Imago BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase II","graph3":"Merck & Co","amount2":1.3500000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":1.3500000000000001,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Ascentage Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Elanco","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Diclazuril","moa":"||Merozoite","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AUM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"AUM001","moa":"||MNK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"Df1001","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"UT Southwestern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Neuphoria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Donepepzil","moa":"||nACh receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Merck & Co","amount2":0.53000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-1167","moa":"nACh-alpha-7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-1167","moa":"nACh-alpha-7 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-1167","moa":"nACh-alpha-7 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-1167","moa":"nACh-alpha-7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Neuphoria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"MK-1167","moa":"nACh-alpha-7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Merck & Co","amount2":0.48999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.48999999999999999,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Olatec Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapansutrile","moa":"||NACHT, LRR and PYD domains-containing protein 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Nectin-4 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Zilovertamab Vedotin","moa":"Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Zilovertamab Vedotin","moa":"Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zilovertamab Vedotin","moa":"Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Zilovertamab Vedotin","moa":"Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Zilovertamab Vedotin","moa":"Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Zilovertamab Vedotin","moa":"Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zilovertamab Vedotin","moa":"Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zilovertamab Vedotin","moa":"Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Zilovertamab Vedotin","moa":"Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MK-4464","moa":"NK cell","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Expanded Collaboration","leadProduct":"MK-4464","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Celyad","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Celyad Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CYAD-101","moa":"NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Ruzasvir","moa":"||Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Atea Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MK-8591A","moa":"NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-8591A","moa":"NRTT","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X purinoceptor 3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X purinoceptor 3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"IDE161","moa":"||PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Anaveon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ANV600","moa":"PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Fujifilm holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"MEDSIR","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Roche Diagnostics GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novocure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"MEDSIR","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Pfizer Inc | Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Pfizer Inc | Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"European Network for Gynaecological Oncological Trial Groups | GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ European Network for Gynaecological Oncological Trial Groups | GOG Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ European Network for Gynaecological Oncological Trial Groups | GOG Foundation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"GOG Foundation | European Network for Gynaecological Oncological Trial Groups","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ GOG Foundation | European Network for Gynaecological Oncological Trial Groups","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ GOG Foundation | European Network for Gynaecological Oncological Trial Groups"},{"orgOrder":0,"company":"Merck & Co","sponsor":"European Network for Gynaecological Oncological Trial Groups | GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ European Network for Gynaecological Oncological Trial Groups | GOG Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ European Network for Gynaecological Oncological Trial Groups | GOG Foundation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Japan Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Japan Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Japan Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Pfizer Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Seagen"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Reflexion Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Reflexion Medical","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Reflexion Medical"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PDS Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Presage Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"UT Southwestern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Yukinori Ozaki","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Yukinori Ozaki","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Yukinori Ozaki"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Incyte Corporation | Stephen Shiao","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Incyte Corporation | Stephen Shiao","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Incyte Corporation | Stephen Shiao"},{"orgOrder":0,"company":"Merck & Co","sponsor":"CEL-SCI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ CEL-SCI","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ CEL-SCI"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"LM-299","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":3.29,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.29,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"LM-299","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":3.29,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.29,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Avelumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Pfizer Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Termination","leadProduct":"Bintrafusp Alpha","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ GSK"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BH3120","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"BH3120","moa":"||PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Verona Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":10,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":10,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"KalVista Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Termination","leadProduct":"KVD001","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Merck & Co","amount2":0.76000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.76000000000000001,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"WM382","moa":"PMIX\/PMX","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Nerviano Medical Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"NMS-03305293","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Redx Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RXC004","moa":"Porcupine","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Organon","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Desogestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Newco","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Demerger","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Merck & Co \/ Newco","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Newco"},{"orgOrder":0,"company":"Organon","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Demerger","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Financing","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ulipristal Acetate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Organon","sponsor":"IQVIA | OSTAtistics","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NOMAC-E2","moa":"Progesterone receptor\/Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Organon \/ IQVIA | OSTAtistics","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ IQVIA | OSTAtistics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MK-0616","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"MK-0616","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"MK-0616","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Adlai Nortye","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AN0025","moa":"Prostaglandin E2 receptor EP4 (PTGER4)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Organon","sponsor":"ObsEva","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Ebopiprant","moa":"prostaglandin receptor antagonists","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Organon","amount2":1,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"8","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"QBiotics Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Tigilanol Tiglate","moa":"||Protein kinase C (PKC)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ QBiotics Group","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ QBiotics Group"},{"orgOrder":0,"company":"Merck & Co","sponsor":"QBiotics Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tigilanol Tiglate","moa":"Protein kinase C (PKC)","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Collaboration","leadProduct":"177-Lu Rosopatamab Tetraxetan","moa":"||PSMA","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Organon","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"Pertuzumab","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Organon","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Tucatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0.28000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"Receptor tyrosine-protein kinase erbB-3 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"Patritumab Deruxtecan","moa":"Receptor tyrosine-protein kinase erbB-3 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":22,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":22,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"Receptor tyrosine-protein kinase erbB-3 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"Receptor tyrosine-protein kinase erbB-3 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"Receptor tyrosine-protein kinase erbB-3 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"Receptor tyrosine-protein kinase erbB-3 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"Receptor tyrosine-protein kinase erbB-3 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"Receptor tyrosine-protein kinase erbB-3 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"Receptor tyrosine-protein kinase erbB-3 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"Receptor tyrosine-protein kinase erbB-3 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CA-4948","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Urology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Johnson & Johnson","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Johnson & Johnson"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"ABL Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Themis Bioscience \/ Themis Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"Themis Bioscience \/ Themis Bioscience"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Themis Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Themis Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series B Financing","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Yumanity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Merck & Co","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Vaccinex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Vaccinex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Miransertib","moa":"Serine\/threonine-protein kinase AKT","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Encorafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Encorafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Prelude Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PRT3789","moa":"SMARCA2","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Prelude Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Docetaxel","moa":"||SMARCA2","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ertugliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ertugliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ertugliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Digoxin","moa":"Sodium\/potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Riociguat","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Riociguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Bayer AG"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Bayer AG"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MK-5475","moa":"Soluble guanylate cyclase (GCS)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MK-5475","moa":"Soluble guanylate cyclase (GCS)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Frespaciguat","moa":"Soluble guanylate cyclase (sGC)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Frespaciguat","moa":"Soluble guanylate cyclase (sGC)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SNX281","moa":"Stimulator of interferon genes protein (TMEM173)","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"TME Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"Stromal cell-derived factor 1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Celerion"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Genentech"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"PR600","moa":"TNF receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus Biosciences \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"PR600","moa":"TNF receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus Biosciences \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"PR600","moa":"TNF receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus Biosciences \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BI-1910","moa":"TNF2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||TNF2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BI-1808","moa":"TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Samsung Bioepis"},{"orgOrder":0,"company":"Merck & Co","sponsor":"TILT Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ TILT Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ TILT Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"TILT Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"TILT-123","moa":"TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"TILT Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"TILT-123","moa":"TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Dermatology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Prometheus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":10.800000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":10.800000000000001,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Dermatology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Thermo Fisher Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Thermo Fisher Scientific","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Thermo Fisher Scientific"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Highlight Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BO-112","moa":"Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Highlight Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BO-112","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Highlight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"BO-112","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Highlight Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Highlight Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"4D Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"4D Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"4D Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eikon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BDB018","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eikon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EIK1001","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bezlotoxumab","moa":"Toxin B","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PMV Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rezatapopt","moa":"TP53*","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PMV Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rezatapopt","moa":"||TP53*","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PMV Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Rezatapopt","moa":"||TP53*","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ PMV Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ PMV Pharma"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Hematology","graph2":"Approved FDF","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Acceleron Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Acceleron Pharma \/ Acceleron Pharma"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Acceleron Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron Pharma \/ Acceleron Pharma"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Oncology","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ACE-1334","moa":"Transforming growth factor beta 1 (TGFB1)","graph1":"Immunology","graph2":"Phase I","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Allyl Isothiocyanate","moa":"transient","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"European Network for Gynaecological Oncological Trial Groups | GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ European Network for Gynaecological Oncological Trial Groups | GOG Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ European Network for Gynaecological Oncological Trial Groups | GOG Foundation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"European Network for Gynaecological Oncological Trial Groups | GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ European Network for Gynaecological Oncological Trial Groups | GOG Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ European Network for Gynaecological Oncological Trial Groups | GOG Foundation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"European Network for Gynaecological Oncological Trial Groups | GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ European Network for Gynaecological Oncological Trial Groups | GOG Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ European Network for Gynaecological Oncological Trial Groups | GOG Foundation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Sichuan Kelun-Biotech Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Sichuan Kelun-Biotech Biopharmaceutical"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Undisclosed","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Collaboration","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Ladiratuzumab Vedotin","moa":"Tubulin | Zinc transporter ZIP6","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":4.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":4.2000000000000002,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Ladiratuzumab Vedotin","moa":"||Tubulin | Zinc transporter ZIP6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":1,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Organon","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Atacicept","moa":"Tumor necrosis factor ligand superfamily member 13B | Tumor necrosis factor ligand superfamily member 13","graph1":"Nephrology","graph2":"Phase II","graph3":"Merck & Co","amount2":0.70999999999999996,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.70999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Vera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Vera Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Genprex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Genprex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Gilead Sciences"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"||Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"ArQule","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"ARQ 531","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":2.7000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":2.7000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"129Xe-Hyperpolarized","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"14-C MK-1084","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"14-C MK-5475","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"14-C MK-8189","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"14-C MK-8527","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bio Farma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"4-Valent HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"9-Valent HPV Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Artiva Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"AB-MK-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":1.8700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.8700000000000001,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"BJ Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"BJ-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CHS-388","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CMN-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Curon Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"CN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":1.3,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Curon Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"CN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":1.3,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Expanded Collaboration","leadProduct":"CoV RBD219-N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CoV RBD219-N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Baylor College of Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"DF6215","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"DS-6000a","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"DTap, Inactivated Poliovirus, Haemophilus B Conjugate and Hepatitis B Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"DTaP-IPV-Hib-HepB Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GABON","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ebola Zaire Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ebola Zaire Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ebola Zaire Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Lumos Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ebola Zaire Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Enclitide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Celerion"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Enlicitide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Enlicitide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide Chloride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Enlicitide Chloride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Enlicitide Chloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide Chloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Enlicitide Decanoate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Enlicitide Decanoate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide Decanoate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide Decanoate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Enlicitide Decanoate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Enlicitide Decanoate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide Decanoate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide Decanoate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide Decanoate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Enlicitide Decanoate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Evaxion Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EVX-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Evaxion Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Expanded Collaboration","leadProduct":"EVX-B2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"EyeBio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":3,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":3,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"EyeBio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":3,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":3,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"EYE201","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"1ST Biotherapeutics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FB849","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Gebasaxturev","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"GI Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"GI-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"GI Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"GI-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"GV20 Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GV20-0251","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"GV20 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"GV20-0251","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GX-188E","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hepatitis B (Recombinant) Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Chongqing Zhifei Biological Products","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":14.800000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":14.800000000000001,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ DKSH"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HPV Quadrivalent Types 6, 11, 16, and 18 Vaccine Recombinant","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SLOVENIA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"HS-10535","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Merck & Co","amount2":2.0099999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.0099999999999998,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HSV 2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Human Papillomavirus 9-valent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Human Papillomavirus 9-valent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Human Papillomavirus 9-valent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Human Papillomavirus 9-valent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Human Papillomavirus 9-valent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JZP898","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Microbiotica","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"MB097","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"OPKO Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"MDX-2201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Measles, Mumps, Rubella and Varicella Virus Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MK-0472","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MK-0482","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MK-1045","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-1045","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MK-1088","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-1200","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-1708","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-1708","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MK-1942","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MK-1942","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MK-1942","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MK-2214","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-2214","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MK-2225","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MK-2225","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-2828","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-3120","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MK-3402","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-4318","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-4646","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-4700","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MK-5720","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Agreement","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MK-6194","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MK-6194","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MK-6194","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-6194","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-6194","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MK-6194","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MK-6552","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-6552","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-6552","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-6552","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-6552","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MK-6598","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-6837","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-6916","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-7602","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-7602","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MK-7762","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"MK-7762","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-8294","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MK-8507","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MK-8510","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MMR vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Modifi Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"MOD-246","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":1.3300000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.3300000000000001,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"mRNA-1172","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MRNA-4157\/V940","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Multivalent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Themis Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MV-SARS-CoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Themis Bioscience \/ Themis Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Themis Bioscience \/ Themis Bioscience"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Nonavalent Hpv Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Nouscom AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"MVA-209-FSP","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Organon","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OG-6219","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Organon \/ IQVIA"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Pneumococcal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pneumococcal Vaccine Polyvalent, Sterile, Liquid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Rotavirus Vaccine, Live, Oral, Pentavalent","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"rVSV Based Covid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ IAVI","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ IAVI"},{"orgOrder":0,"company":"Merck & Co","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"rVSV\u2206G-LASV-GPC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"S-531011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sichuan Kelun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"SKB571","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SLC-391","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Phanes Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Spevatamig","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Toragen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ulevostinag","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"V110","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"V114","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"V114","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"V118C","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V181","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"V181","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Butantan Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"V181","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"V330","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"V350A","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"V350A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"V503","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"V540B","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"V540D","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"V590","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.5,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.5,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.5,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ SVB Leerink"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Prometheus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":10.800000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":10.800000000000001,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Celerion"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase I","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase I","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Celerion"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Financing","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Prometheus Biosciences","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Eventide Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Prometheus Biosciences \/ Eventide Asset Management"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PharmAbcine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Olinvacimab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PharmAbcine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Olinvacimab","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Olinvacimab","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ PharmAbcine","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ PharmAbcine"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||VEGF gene producer","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Tiumbio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TU2218","moa":"VEGFR1\/VEGFR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"HMBD-002","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"HMBD-002","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Kineta","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"KVA12123","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Warfarin Sodium","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"Voltage-gated potassium channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||Wilms tumor protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||Wilms tumor protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cyprumed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0.48999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.48999999999999999,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Proxygen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRIA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":2.5499999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":2.5499999999999998,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Merck & Co","amount2":2.5499999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.5499999999999998,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sichuan Kelun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":9.4800000000000004,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":9.4800000000000004,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"HitGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sichuan Kelun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0.93999999999999995,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":9.4800000000000004,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sichuan Kelun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":1.4099999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.4099999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Var2 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Mestag Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Mestag Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":1.8999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"IRBM","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Epitopea","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Curve Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":1.7,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Aqilion","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Merck & Co","amount2":1.03,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":1.03,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"IRBM","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Almac Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cytoreason","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0.20999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.20999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Organon","sponsor":"Cirqle Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Organon","amount2":0.37,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.37,"dosageForm":"Gel","sponsorNew":"Organon \/ Cirqle Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Organon \/ Cirqle Biomedical"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Takara Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Takara Bio","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Takara Bio"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Vesselon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Vesselon","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Vesselon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novocure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Novocure","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Novocure"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Dewpoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0.46000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":0.46000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":1.3799999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":1.3799999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cerevance","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Merck & Co","amount2":1.1299999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.1299999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Zymeworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0.89000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.89000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cerevance","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Merck & Co","amount2":1.1299999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.1299999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pearl Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":1,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Afrigen Biologics and Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Afrigen Biologics and Vaccines","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Afrigen Biologics and Vaccines"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cerevance","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Merck & Co","amount2":1.1299999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.1299999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Foghorn Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0.42999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.42999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Skyhawk Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0.59999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.59999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AbSci","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hackensack Meridian CDI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Yumanity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0.5,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.5,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0.5,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.5,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"A2 Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Merck & Co","amount2":0.54000000000000004,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.54000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Janux Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":1,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"C4 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0.60999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.60999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0.82999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.82999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Merck & Co","amount2":3.6499999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":3.6499999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Amathus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Merck & Co","amount2":0.5,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.5,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Caraway Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Merck & Co","amount2":0.60999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.60999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Xeris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Vaxxas","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Starpharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Starpharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Evaxion Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Licensing Agreement","leadProduct":"EVX-B3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0.59999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.59999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0.34999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.34999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Merck & Co"}]

Find Clinical Drug Pipeline Developments & Deals by Merck & Co

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Bildyos (denosumab) is a biosimilar antibody candidate, which is approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

                          Product Name : Bildyos

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          September 02, 2025

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Recipient : Shanghai Henlius Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : MK-2828 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 28, 2025

                          Lead Product(s) : MK-2828

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : MK-2214 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Alzheimer Disease.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 24, 2025

                          Lead Product(s) : MK-2214

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : MK-1084 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Colonic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 30, 2025

                          Lead Product(s) : MK-1084

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Keytruda (Pembrolizumab) is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                          Product Name : Keytruda

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          April 30, 2025

                          Lead Product(s) : Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Rabin Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : MK-1084 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 24, 2025

                          Lead Product(s) : MK-1084

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Opevesostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 05, 2025

                          Lead Product(s) : Opevesostat

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : MK-4482 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 10, 2025

                          Lead Product(s) : Molnupiravir

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : MK-3120 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 10, 2025

                          Lead Product(s) : MK-3120

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : MK-1084 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Diseases.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 07, 2025

                          Lead Product(s) : MK-1084

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank